id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-0630-0006,FDA,FDA-2016-E-0630,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-12-13T05:00:00Z,2016,12,2016-12-13T05:00:00Z,,2016-12-13T16:09:34Z,,0,0,09000064824012b6
FDA-2016-E-0630-0005,FDA,FDA-2016-E-0630,"Determination of Regulatory Review Period for Purposes of Patent
Extension; GARDASIL 9",Notice,Determinations,2016-12-07T05:00:00Z,2016,12,2016-12-07T05:00:00Z,2017-02-07T04:59:59Z,2016-12-07T14:56:23Z,2016-29303,0,0,09000064823e7947
FDA-2016-E-0630-0004,FDA,FDA-2016-E-0630,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2016-10-13T04:00:00Z,2016,10,2016-10-13T04:00:00Z,,2016-10-13T14:47:51Z,,0,0,09000064822ea5ef
FDA-2016-E-0630-0003,FDA,FDA-2016-E-0630,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-05-02T04:00:00Z,2016,5,2016-05-02T04:00:00Z,,2016-05-02T23:20:38Z,,0,0,0900006481fa1d48
FDA-2016-E-0630-0001,FDA,FDA-2016-E-0630,Patent Extension Application from Merck Sharp & Dohme Corp.,Other,Application,2016-02-24T05:00:00Z,2016,2,2016-02-24T05:00:00Z,,2016-02-25T00:39:23Z,,0,0,0900006481e7bb64
FDA-2016-E-0630-0002,FDA,FDA-2016-E-0630,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-02-24T05:00:00Z,2016,2,2016-02-24T05:00:00Z,,2016-02-25T00:39:58Z,,0,0,0900006481e7bb66